
|Articles|November 1, 2012
Product Preview
Products and services in the pipeline from Nymox Pharmaceuticals Corp.; OncoGenex Pharmaceuticals, Inc.; Ampio Pharmaceuticals, Inc.; Aragon Pharmaceuticals; Sophiris Bio Inc.; Genomic Health, Inc.; OxThera AB; Aeterna Zentaris Inc.; and Tengion, Inc.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Modern frameworks for treating high-risk non–muscle invasive bladder cancer
5


















